News

A recently published review reinforces ketogenic diet therapies as a clinically relevant option for epilepsy, particularly in pediatric and metabolic populations, while underscoring the need for more rigorous evidence to guide their optimal use.

Catch up on any of the neurology headlines you may have missed in April 2026, compiled into 1 place by the NeurologyLive® team.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Greg Pontone, MD, MHS. [LISTEN TIME: 18 minutes]

FDA clears AXS-05 to ease Alzheimer dementia agitation, offering an oral option that significantly delays symptom relapse in long-term data.

Amy Waldman, MD, associate professor of neurology at the Perelman School of Medicine at the University of Pennsylvania, breaks down phase 1–3 data showing zilganersen’s potential to modify disease progression in Alexander disease.

Findings from the phase 2 ADDRESS-LC trial, assessing BioVie’s bezisterim in patients with long COVID–related fatigue and cognitive impairment, are anticipated to be reported in the first half of 2026.

Machine learning will only transform clinical neurology if predictive accuracy is matched by usability, transparency, and active physician involvement in the design and implementation of tools that support patient care.

GMRx2 reduced recurrent stroke risk by 39% in patients with prior intracerebral hemorrhage in the phase 3 TRIDENT trial, supporting single-pill intensive blood pressure control as a promising secondary prevention strategy.

Phase 1 data presented at AAN 2026 suggest that investigational siRNA therapy RAG-17 may reduce key disease biomarkers and show early signs of clinical stabilization following a single dose in patients with SOD1-ALS.

The director of the Center for Neurological Restoration at Cleveland Clinic discussed long-term TEMPO-4 data evaluating tavapadon’s impact on symptom control and levodopa utilization in Parkinson disease.

New long-term and post hoc data presented at the 2026 AAN Annual Meeting highlighted durable efficacy, safety, and patient-centered outcomes with nipocalimab in antibody-positive generalized myasthenia gravis.

The founder and president of the Indian Federation of Neurorehabilitation highlighted emerging technologies and evolving therapeutic strategies shaping the future of neurorehabilitation. [WATCH TIME: 5 minutes]

Jaime Ramos, PhD, Assistant Professor of Psychiatry and Neurology at NYU Grossman School of Medicine, discussed the role of neutrophil-to-lymphocyte ratio as a scalable inflammatory marker associated with future dementia risk.

CHMP has recommended tolebrutinib for nonrelapsing SPMS following phase 3 data showing reduced disability progression, supporting its role in targeting CNS-driven inflammation.

A duo of Baptist Health experts discussed emerging evidence suggesting that hormonal factors, sex-based clinical differences, and social roles contribute to distinct experiences for women with Parkinson disease.

The deputy director at Association of Movement Disorder Advanced Practice Providers (AMDAPP) recapped key themes in movement disorders presented at the 2026 AMDAPP conference. [WATCH TIME: 5 minutes]

Phase 3 data presented at AAN 2026 show that IVIG improves response rates in patients with autoimmune encephalitis refractory to steroids, supporting its role as a second-line immunotherapy option.

Here's some of what is coming soon to NeurologyLive® this week.

New pharmacokinetic data presented at AAN 2026 show that adolescents with focal epilepsy achieve cenobamate exposures comparable to adults, supporting simplified fixed-dose strategies and informing future pediatric development.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the MOGAD pipeline!

The assistant professor in the Department of Chemistry and Biochemistry at University of Nevada, Las Vegas reflected on receiving the first MDA Research Momentum Award at the 2026 MDA Conference. [WATCH TIME: 2 minutes]

Neurology News Network for the week ending April 25th, 2026. [WATCH TIME: 5 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 24, 2026.

A recent study suggested that probiotic regimens and biomarker-guided strategies may be a promising signal for reducing excessive daytime sleepiness in patients with PD and CKD.

Mitzi Joi Williams, MD, and Carol Coleman break down insurance basics, prior authorizations, and practical strategies to help patients navigate cost and access challenges at the start of the year.

A national survey presented at AAN 2026 revealed significant gaps between patients with epilepsy and clinicians in seizure expectations, treatment decisions, and communication around risks like SUDEP.

The neurologist at the University of Oklahoma Medical Center highlighted early diagnosis, prevention of secondary injury, and multimodal monitoring as key to improving patient outcomes in TBI. [WATCH TIME: 5 minutes]

FDA issues complete response letter for GTx-104 in aneurysmal subarachnoid hemorrhage, citing manufacturing and nonclinical concerns despite positive phase 3 efficacy and safety data.